American Journal of Pharmacogenomics

, Volume 5, Issue 2, pp 93–99 | Cite as

Platelet Glycoprotein IIb/IIIa Polymorphism and Coronary Artery Disease

Implications for Clinical Practice
  • Augusto Di Castelnuovo
  • Giovanni de Gaetano
  • Maria Benedetta Donati
  • Licia IacovielloEmail author
Genomics in Health and Disease


Membrane glycoprotein (GP) IIb/IIIa plays a major role in platelet function; indeed it enables stimulated platelets to bind fibrinogen and related adhesive proteins, a process that is considered key in the development of thrombosis. The gene encoding GPIIIa (ITGB3, also known as GP3A) shows a common platelet antigen polymorphism [PL(A1)/PL(A2); expressed by alleles ITGB3*001 and ITGB3*002] that was variably associated with vascular disease. In 1996, the presence of the PL(A2) allele (ITGB3*001) was first reported to increase the risk of coronary heart disease. Shortly after, the interest in this study was increased by the publication of a case report on the death from myocardial infarction of an Olympic athlete who was found to be homozygous for the PL(A2) allele. Overviews of the published studies on the PL(A1)/PL(A2) polymorphism and coronary risk suggest an influence of the PL(A2) allele on the clinical phenotype and the interaction with other environmental factors. In particular, the strongest effect of the ITGB3 PL(A2) allele was expressed on the risk of occlusion after revascularization procedures, mainly after stent implantation, a condition in which platelet activation is more important as compared with other stenotic mechanisms.

In the future, the identification of patients who are particularly responsive to GPIIb/IIIa antagonist therapy (e.g. those with the PL(A2) allele) might help to improve the treatment efficacy in this relatively small population. In a mechanism possibly unrelated to its effect on platelet reactivity to aggregating stimuli, the presence of the PL(A2) allele might influence the antiaggregatory effect of platelet inhibitory drugs such as aspirin (acetylsalicylic acid), clopidogrel, and GPIIb/IIIa antagonists.

Although interesting, current data does not yet have direct clinical implications for patient risk identification and drug therapy tailoring. Larger studies are necessary to define the role of the PL(A2) allele in more homogeneous groups where platelet GPIIb/IIIa activation might be particularly relevant.


Coronary Artery Disease Aspirin Platelet Function Abciximab Platelet Reactivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by a grant from the Italian Ministry of Health, Rome, Italy (contract no. 211 RF 2002) and by the EU project IMMIDIET QLK1-CT-2000-00100.

The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Peerschke EIB, Lopez JA. Platelet membranes and receptors. In: Loscalzo J, Schafer AI, editors. Thrombosis and hemorrhage. 2nd ed. Baltimore (MD): Williams & Wilkins, 1998: 229Google Scholar
  2. 2.
    Andrews RK, Shen Y, Gardiner EE, et al. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 1999; 82: 357–64PubMedGoogle Scholar
  3. 3.
    Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553–9PubMedCrossRefGoogle Scholar
  4. 4.
    Nurden AT. Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Thromb Haemost 1995; 74: 345–51PubMedGoogle Scholar
  5. 5.
    Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992; 80: 1386–404PubMedGoogle Scholar
  6. 6.
    Newman PJ. Platelet alloantigens: cardiovascular as well as immunological risk factors? Lancet 1997; 349: 370–1PubMedCrossRefGoogle Scholar
  7. 7.
    Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090–4PubMedCrossRefGoogle Scholar
  8. 8.
    Goldschmidt-Clermont PJ, Shear WS, Schwartzberg J, et al. Clues to the death of an Olympic champion [letter]. Lancet 1996; 347: 1833PubMedCrossRefGoogle Scholar
  9. 9.
    Di Castelnuovo A, de Gaetano G, Donati MB, et al. Platelet glycoprotein receptor IIIa polymorphism PL(A1)/PL(A2) and coronary risk: a meta-analysis. Thromb Haemost 2001; 85: 626–33PubMedGoogle Scholar
  10. 10.
    Ridker PM, Hennekens CH, Schmitz C, et al. Pl(A1)/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet 1997; 349: 385–8PubMedCrossRefGoogle Scholar
  11. 11.
    Aleksic N, Juneja H, Folsom AR, et al. Platelet Pl(A2) allele and incidence of coronary heart disease: results from the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2000; 102: 1901–5PubMedCrossRefGoogle Scholar
  12. 12.
    Bray PF, Cannon CP, Goldschmidt-Clermont P, et al. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88: 347–52PubMedCrossRefGoogle Scholar
  13. 13.
    Mikkelsson J, Perola M, Penttila A, et al. The GPIIIa (β3 integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis 2001; 154: 721–7PubMedCrossRefGoogle Scholar
  14. 14.
    Mikkelsson J, Perola M, Laippala P, et al. Glycoprotein IIIa Pl (A1/A2) polymorphism and sudden cardiac death. J Am Coll Cardiol 2000; 36: 1317–23PubMedCrossRefGoogle Scholar
  15. 15.
    Grove EL, Orntoft TF, Lassen JF, et al. The platelet polymorphism Pl(A2) is a genetic risk factor for myocardial infarction. J Intern Med 2004; 255: 637–44PubMedCrossRefGoogle Scholar
  16. 16.
    Doll R. The use of meta-analysis in epidemiology: diet and cancers of the breast and colon. Nutr Rev 1994; 52: 233–7PubMedCrossRefGoogle Scholar
  17. 17.
    Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa Pl(A1)/A2 polymorphism with myocardial infarction. Am J Cardiol 2000; 86: 1000–5PubMedCrossRefGoogle Scholar
  18. 18.
    Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001; 87: 1361–6PubMedCrossRefGoogle Scholar
  19. 19.
    Burr D, Doss H, Cooke GE, et al. A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat Med 2003; 22: 1741–60PubMedCrossRefGoogle Scholar
  20. 20.
    Eriksson P, Kallin B, van’t Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851–5PubMedCrossRefGoogle Scholar
  21. 21.
    Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817–21PubMedGoogle Scholar
  22. 22.
    Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117–22Google Scholar
  23. 23.
    Bojesen SE, Juul K, Schnohr P, et al. Platelet glycoprotein IIb/IIIa Pl(A2)/Pl(A2) homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study. J Am Coll Cardiol 2003 Aug 20; 42: 661–7PubMedCrossRefGoogle Scholar
  24. 24.
    Kastrati A, Schomig A, Seyfarth M, et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999; 99: 1005–10PubMedCrossRefGoogle Scholar
  25. 25.
    Pastinen T, Perola M, Niini P, et al. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Genet 1998; 7: 1453–62PubMedCrossRefGoogle Scholar
  26. 26.
    Herrmann SM, Poirier O, Marques-Vidal P, et al. The Leu33/Pro polymorphism (PL(A1)/Pl(A2)) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study: etude cas-temoins de l’infarctus du myocarde. Thromb Haemost 1997; 77: 1179–81PubMedGoogle Scholar
  27. 27.
    Gardemann A, Humme J, Stricker J, et al. Association of the platelet glycoprotein IIIa Pl(A1)/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost 1998; 80: 214–7PubMedGoogle Scholar
  28. 28.
    Walter DH, Schachinger V, Elsner M, et al. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997; 350: 1217–9PubMedCrossRefGoogle Scholar
  29. 29.
    Mamotte CD, van Bockxmeer FM, Taylor RR. PIa1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol 1998; 82: 13–6PubMedCrossRefGoogle Scholar
  30. 30.
    Abbate R, Marcucci R, Camacho-Vanegas O, et al. Role of platelet glycoprotein PL (A1/A2) polymorphism in restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1998; 82: 524–5PubMedCrossRefGoogle Scholar
  31. 31.
    Laule M, Cascorbi I, Stangl V, et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet 1999; 353: 708–12PubMedCrossRefGoogle Scholar
  32. 32.
    Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994; 343: 881–6PubMedCrossRefGoogle Scholar
  33. 33.
    de Gaetano G, Cerletti C, Iacoviello L. Pharmacogenetics as a new antiplatelet strategy: platelets in thrombotic and non thrombotic disorders. In: Gresele P, Page CP, Fuster V, et al., editors. Platelets in thrombotic and non-thrombotic disorders: pathophysiology, pharmacology and therapeutics. Cambridge: Cambridge University Press, 2002: 964–77CrossRefGoogle Scholar
  34. 34.
    Coller BS, Seligsohn U, Peretz H, et al. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol 1994; 31: 301–11PubMedGoogle Scholar
  35. 35.
    Coller BS. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost 1999; 82: 326–36PubMedGoogle Scholar
  36. 36.
    Vijayan KV, Goldschmidt-Clermont PJ, Roos C, et al. The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 2000; 105: 793–802PubMedCrossRefGoogle Scholar
  37. 37.
    Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa Pl(A2) polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999; 19: 1142–7PubMedCrossRefGoogle Scholar
  38. 38.
    Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013–8PubMedCrossRefGoogle Scholar
  39. 39.
    Goldschmidt-Clermont P, Weiss E, Shear W, et al. Platelets from PL(A2)(−) individuals bind more exogenous fibrinogen than platelets from PL(A2)(+) individuals [abstract]. Blood 1996; 88: 26aGoogle Scholar
  40. 40.
    Lasne D, Krenn M, Pingault V, et al. Interdonor variability of platelet response to thrombin receptor activation: influence of Pl(A2) polymorphism. Br J Haematol 1997; 99: 801–7PubMedCrossRefGoogle Scholar
  41. 41.
    Goodall AH, Curzen N, Panesar M, et al. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, Pl(A2), Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999; 20: 742–7PubMedCrossRefGoogle Scholar
  42. 42.
    Andrioli G, Minuz P, Solero P, et al. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 2000; 110: 911–8PubMedCrossRefGoogle Scholar
  43. 43.
    Bray PF. Integrin polymorphisms as risk factors for thrombosis. Thromb Haemost 1999; 82: 337–44PubMedGoogle Scholar
  44. 44.
    Cooke GE, Bray PF, Hamlington JD, et al. Pl(A2) polymorphism and efficacy of aspirin. Lancet 1998; 351: 1253PubMedCrossRefGoogle Scholar
  45. 45.
    Undas A, Sanak M, Musial J, et al. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982–3PubMedCrossRefGoogle Scholar
  46. 46.
    Szczeklik A, Undas A, Sanak M, et al. Relationship between bleeding time, aspirin and the Pl(A1)/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000; 110: 965–7PubMedCrossRefGoogle Scholar
  47. 47.
    Iacoviello L, Donati MB. Interpretation of thrombosis prevention trial [letter]. Lancet 1998; 351: 1205PubMedCrossRefGoogle Scholar
  48. 48.
    Iacoviello L, Di Castelnuovo A, De Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79–85PubMedCrossRefGoogle Scholar
  49. 49.
    Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343: 774–80PubMedCrossRefGoogle Scholar
  50. 50.
    O’Connor FF, Shields DC, Fitzgerald A, et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98: 3256–60PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Augusto Di Castelnuovo
    • 1
  • Giovanni de Gaetano
    • 1
  • Maria Benedetta Donati
    • 1
  • Licia Iacoviello
    • 1
    Email author
  1. 1.Research Laboratories, Centre for High Technology Research and Education in Biomedical SciencesCatholic UniversityCampobassoItaly

Personalised recommendations